CLINGEN ACTIONABILITY
Update History
Syndrome: Factor V Leiden, Heterozygous
Gene/Gene Panel: F5
Updated By
Date
Status
Release
Outcome-Interventions
Notes
Genboree Administrator Account
2018/11/01
Released
1.2.2
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
Internal system migration related to score text replacement from E to N
Liz Webber
2018/04/09
Released
1.2.1
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
Actionability Consensus Scorer
2018/03/19
Released
1.2.0
(Under Revision)
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
Actionability Consensus Scorer
2018/03/19
Released
1.1.0
(Under Revision)
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
Kathleen Mittendorf
2018/01/11
Released
1.0.1
(Under Revision)
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
Elizabeth Clarke
2017/10/23
Released
1.0.0
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
¤ Powered by BCM's Genboree.